BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 17387156)

  • 1. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
    Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
    Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
    Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
    Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
    Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
    J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
    Huang SS; Lee MH; Leu HS
    J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies.
    Trecarichi EM; Tumbarello M; Spanu T; Caira M; Fianchi L; Chiusolo P; Fadda G; Leone G; Cauda R; Pagano L
    J Infect; 2009 Apr; 58(4):299-307. PubMed ID: 19272650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae.
    Henshke-Bar-Meir R; Yinnon AM; Rudensky B; Attias D; Schlesinger Y; Raveh D
    Infection; 2006 Apr; 34(2):66-74. PubMed ID: 16703295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of extended-spectrum beta-lactamases.
    Rodríguez-Baño J; Pascual A
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):671-83. PubMed ID: 18847405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases.
    Endimiani A; Luzzaro F; Brigante G; Perilli M; Lombardi G; Amicosante G; Rossolini GM; Toniolo A
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2598-605. PubMed ID: 15980325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome.
    Tumbarello M; Spanu T; Sanguinetti M; Citton R; Montuori E; Leone F; Fadda G; Cauda R
    Antimicrob Agents Chemother; 2006 Feb; 50(2):498-504. PubMed ID: 16436702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
    Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors associated with extended-spectrum β-lactamase-producing Enterobacteriaceae nosocomial bloodstream infections in a tertiary care hospital: a clinical and molecular analysis.
    Muro S; Garza-González E; Camacho-Ortiz A; González GM; Llaca-Díaz JM; Bosques F; Rositas F
    Chemotherapy; 2012; 58(3):217-24. PubMed ID: 22814216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome.
    Kim SH; Kwon JC; Choi SM; Lee DG; Park SH; Choi JH; Yoo JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
    Ann Hematol; 2013 Apr; 92(4):533-41. PubMed ID: 23161391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detecting risk and predicting patient mortality in patients with extended-spectrum β-lactamase-producing Enterobacteriaceae bloodstream infections.
    Trecarichi EM; Cauda R; Tumbarello M
    Future Microbiol; 2012 Oct; 7(10):1173-89. PubMed ID: 23030423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.
    Du B; Long Y; Liu H; Chen D; Liu D; Xu Y; Xie X
    Intensive Care Med; 2002 Dec; 28(12):1718-23. PubMed ID: 12447513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Wang SS; Lee NY; Hsueh PR; Huang WH; Tsui KC; Lee HC; Wu CJ; Chang CM; Huang CC; Huang CF; Ko WC
    J Microbiol Immunol Infect; 2011 Aug; 44(4):282-8. PubMed ID: 21524962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia.
    Menashe G; Borer A; Yagupsky P; Peled N; Gilad J; Fraser D; Riesenberg K; Schlaeffer F
    Scand J Infect Dis; 2001; 33(3):188-93. PubMed ID: 11303808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mortality risk factors for bloodstream infections caused by extended-spectrum beta-lactamase-producing microorganisms].
    Ferrández O; Grau S; Saballs P; Luque S; Terradas R; Salas E
    Rev Clin Esp; 2011 Mar; 211(3):119-26. PubMed ID: 21371702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.